| Literature DB >> 23399422 |
D M Skowronski1, N Z Janjua, G De Serres, J A Dickinson, A-L Winter, S M Mahmud, S Sabaiduc, J B Gubbay, H Charest, M Petric, K Fonseca, P Van Caeseele, T L Kwindt, M Krajden, A Eshaghi, Y Li.
Abstract
The 2012/13 influenza season in Canada has been characterised to date by early and moderately severe activity, dominated (90%) by the A(H3N2) subtype. Vaccine effectiveness (VE) was assessed in January 2013 by Canada's sentinel surveillance network using a test-negative case-control design. Interim adjusted-VE against medically attended laboratory-confirmed influenza A(H3N2) infection was 45% (95% CI: 13-66). Influenza A(H3N2) viruses in Canada are similar to the vaccine, based on haemagglutination inhibition; however, antigenic site mutations are described in the haemagglutinin gene.Entities:
Mesh：
Substances：
Year: 2013 PMID： 23399422 DOI： 10.2807/ese.18.05.20394-en
Source DB: PubMed Journal: Euro Surveill ISSN： 1025-496X